Compare VCEL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | SRPT |
|---|---|---|
| Founded | 1989 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1997 | 1997 |
| Metric | VCEL | SRPT |
|---|---|---|
| Price | $37.11 | $21.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 29 |
| Target Price | ★ $57.50 | $26.23 |
| AVG Volume (30 Days) | 682.8K | ★ 3.2M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 236.54 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $258,716,999.00 | ★ $2,413,715,000.00 |
| Revenue This Year | $17.86 | $13.72 |
| Revenue Next Year | $18.55 | N/A |
| P/E Ratio | $151.53 | ★ N/A |
| Revenue Growth | 14.05 | ★ 47.15 |
| 52 Week Low | $29.24 | $10.42 |
| 52 Week High | $63.00 | $129.84 |
| Indicator | VCEL | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 56.15 |
| Support Level | $35.53 | $20.14 |
| Resistance Level | $38.09 | $22.97 |
| Average True Range (ATR) | 1.33 | 1.18 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 58.95 | 66.78 |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.